Mantle Cell Lymphoma

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

As research and treatment options for patients with mantle cell lymphoma continue to expand, the development of risk-adapted therapies for the 3 primary subtypes—blastoid, smoldering, and classic broad-spectrum—represents a crucial next step in the field.

Alexey V. Danilov, MD, PhD, discusses the next steps for researching noncovalent BTK inhibitors in mantle cell lymphoma.

Bendamustine plus rituximab followed by autologous stem cell transplant and maintenance rituximab led to comparable outcomes defined by progression-free survival and objective response rate compared with R-CHOP/R-DHAP and ASCT as induction therapy in patients with mantle cell lymphoma.

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.

Maintenance treatment with rituximab following first-line treatment with rituximab plus bendamustine or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone produced an overall survival benefit in older patients with mantle cell lymphoma.

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Treatment with brexucabtagene autoleucel drove durable responses in patients with relapsed/refractory mantle cell lymphoma, particularly those with minimal residual disease negativity at 6 months.

Intensive first-line treatment with high-dose chemotherapy and autologous stem cell transplant was not associated with higher rates of late effects compared with outcomes from less intensive therapies in patients with mantle cell lymphoma.

Anita Kumar, MD, discusses considerations for the use of second-line BTK inhibitors in patients with mantle cell lymphoma who progress on BTK inhibitors.

Maintenance rituximab following first-line bendamustine plus rituximab or a combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone prolonged first-line treatment benefits and improved survival outcomes vs either induction regimen alone.

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.

Brad S. Kahl, MD, discusses unmet needs in mantle cell lymphoma.

The addition of zilovertamab to ibrutinib will be compared with ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma as part of the phase 3 ZILO-301 trial.

Mutations in the p53 gene are associated with poor prognosis for patients with mantle cell lymphoma. Although modern regimens have improved outcomes, those treatments are associated with significant toxicity and, so far, have produced limited efficacy.

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.

Toby Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, discusses the design and the rationale of the phase 3 BRUIN-MCL-321 trial in mantle cell lymphoma.

Single-agent pirtobrutinib is being investigated for safety and efficacy in heavily pretreated, BTK inhibitor–naïve patients with mantle cell lymphoma in the ongoing phase 3 BRUIN-MCL-321 trial.

Ibrutinib in combination with bendamustine and rituximab with rituximab maintenance elicited a significant improvement in progression-free survival compared with standard chemoimmunotherapy in older patients with mantle cell lymphoma.

The use of BTK inhibitors as a frontline treatment improved overall survival vs their deployment in subsequent lines of therapy in patients with mantle cell lymphoma, according to a real-world study (IRB-300004501) published in Blood Advances.

The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

Martin F. Dietrich, MD, PhD, highlights recent updates in mantle cell lymphoma treatment, explains how new developments have raised sequencing questions, and projects where future research efforts will focus.

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Ibrutinib-based combination therapy demonstrated a higher overall response rate and longer progression-free survival compared with ibrutinib alone in patients with relapsed/refractory mantle cell lymphoma.